France· FR:63012197
IMBRUVICA 140 mg, gélule
A medicinal product containing ibrutinib, registered in France by JANSSEN CILAG INTERNATIONAL NV.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- IBRUTINIB
- Manufacturer
- JANSSEN CILAG INTERNATIONAL NV
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip133400927949845flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 90 gélule(s)
- cip133400927949906flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 120 gélule(s)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ibrutinib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandImbruvicaJanssen-Cilag International NV
- SpainIMBRUVICA 140 MG CAPSULAS DURASJanssen-Cilag International N.V
- CzechiaIMBRUVICAJanssen-Cilag International N.V., Beerse
- IrelandIMBRUVICA 140 mg hard capsulesJanssen-Cilag International NV
- IcelandIMBRUVICAJanssen-Cilag International NV*
- NetherlandsIMBRUVICA 140 mg, harde capsulesJanssen-Cilag International NV
- PolandImbruvicaJanssen-Cilag International N.V.
- SwedenIMBRUVICA 140 mg Kapsel, hårdJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Imbruvica
- Liechtenstein · Imbruvica
- Norway · Imbruvica
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/43bb96b3-8aa2-4965-9469-c0a996fdbd8a GET /v1/drugs/43bb96b3-8aa2-4965-9469-c0a996fdbd8a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63012197",
"date_amm": "2014-10-21",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/14/945",
"substance": "IBRUTINIB",
"statut_amm": "Autorisation active",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about ibrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.